> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GBT Sees Positive Results in Phase 3 Voxelotor Trial
- URL: https://www.fdaweb.com/gbt-sees-positive-results-in-phase-3-voxelotor-trial/
- Published: 2018-06-27T12:00:00.000Z
- Updated: 2026-09-15T00:16:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141786

Global Blood Therapeutics say it is in discussions with FDA about accelerated approval for its voxelotor to treat sickle cell anemia based on results from Part A of its Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) study that showed a statistically significant increase in the proportion of patients with greater than 1g/dL increase in hemoglobin versus baseline. Company officials say they believe the results meet the standard for accelerated approval.